AXSOME THERAPEUTICS INC

AXSMNASDAQ

🏆 #873 by market capUS Equity

$186.03▼ $7.46 (−4.01%)

After hours · at close

🔔

Track AXSM

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.0%

7d▼ 8.4%

14d▼ 8.9%

30d▼ 6.5%

ytd▲ 1.8%

1y▲ 58.2%

🏦Market Cap

$9.57B

Small Cap

📈Revenue Growth (YoY)

+56.9%

High Growth

📊Gross Margin

93.2%

High

💵FCF Margin

—

⚖️P/S Ratio

13.3x

Elevated

Otter Score

Fair

Trading Snapshot

Day Range: $184.51 – $188.59
52-Week Range: $115.31 – $260.19
Volume: $1.90B
Avg Volume: $2.53B
Shares Outstanding: 51.5M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $638M
Last Q Revenue: $218M
P/E Ratio: —
P/S Ratio: 13.3x
EPS (TTM): $-3.76
Dividend Yield: —
Dilution (1yr): +4.3%

Why Investors Own AXSM

✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
✓Healthy economics — 57% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AXSOME THERAPEUTICS INC

AXSM

Financial Trends

Revenue

$638M▲ +65.5% YoY

Gross Margin

92.6%▲ +1.3% YoY

Operating Income

−$169M▼ −39.7% YoY

Free Cash Flow

−$94M▼ −27.0% YoY

Shares Outstanding

50.6M▲ +4.3% YoY

Net Cash

$82M▼ −$41M YoY

StockOtter · stockotter.space

About AXSOME THERAPEUTICS INC

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

🦦